of the patients receiving PCI-27483 experienced a thromboembolic event. We are currently in the Phase II portion of the study enrolling patients who receive either gemcitabine alone or gemcitabine plus PCI-27483 (dose at 1.2 mg/kg twice daily). We anticipate completion of enrollment in the Phase II portion during calendar year 2011.Financial Results for Second Quarter Fiscal 2011 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended December 31, 2010 was $6.1 million, or $0.10 per share. This compares with a non-GAAP net loss of $1.4 million, or $0.03 per share, for the fiscal quarter ended December 31, 2009. Reconciliation between GAAP and non-GAAP results is provided at the end of this press release.
The GAAP net loss for the fiscal quarter ended December 31, 2010 was $7.5 million, or $0.13 per share. This compares with a GAAP net loss of $0.2 million, or $0.00 per share for the fiscal quarter ended December 31, 2009.
Total revenue was $2.8 million for the fiscal quarter ended December 31, 2010. Upon the signing of a drug supply agreement with Les Laboratoires Servier ("Servier") in the quarter ended December 31, 2009, the company began recognizing revenue from its collaboration agreement with Servier, which was entered into in April 2009. Total revenue for the fiscal quarter ended December 31, 2009 was $4.7 million, of which $1.2 million represents the pro rata portion of revenue attributable to the period from April 2009 (i.e., the signing of the collaboration agreement) to June 30, 2009.
As of December 31, 2010, the company had cash, cash equivalents and marketable securities totaling $61.6 million. This compares with $74.1 million in cash, cash equivalents and marketable securities as of June 30, 2010, our prior fiscal year end. We received the third scheduled payment of $1.0 million from our Collaboration and License Agreement with Les Laboratoires Servier in November 2010 aPage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call2
. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences3
. Pharmacyclics, Inc. Rights Offering Oversubscribed4
. Pharmacyclics Announces Subscription Price for Rights Offering5
. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference6
. Pharmacyclics Files Registration Statement for Rights Offering7
. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results8
. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth9
. Pharmacyclics Secures $5.0 Million in Debt Financing10
. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results11
. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results